NASDAQ · PPCB
Propanc Biopharma, Inc.
$1.86-$0.25 (-12.08%)
Propanc Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
Loading market information…
OTC · TCON · USD
Stock price, earnings
Quote as of Jul 16, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TRACON Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow TRACON Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TRACON Pharmaceuticals, Inc. functions as a biopharmaceutical enterprise, primarily dedicated to the discovery, development, and eventual market launch of cancer treatments within the United States. Its current product pipeline features several assets in various stages of clinical trials. These include envafolimab (KN035), a PD-L1 single-domain antibody being investigated for the treatment of soft tissue sarcoma, and YH001, an experimental humanized CTLA-4 IgG1 monoclonal antibody targeting a range of cancer indications. Further clinical-stage compounds are TRC102, a small molecule undergoing Phase II evaluation for mesothelioma, and Phase I studies for solid tumors, lymphomas, lung cancer, and glioblastoma. Additionally, TJ004309, a CD73 antibody, is in Phase I clinical development for solid tumors. To bolster its development efforts, TRACON has forged a series of collaboration and licensing agreements. These encompass partnerships with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for envafolimab; I-Mab Biopharma for the CD73 antibody TJ004309; and Case Western Reserve University for TRC102. The company also maintains a cooperative research and development agreement with the National Cancer Institute. Established in 2004, the firm was initially known as Lexington Pharmaceuticals, Inc. before officially changing its name to TRACON Pharmaceuticals, Inc. in March 2005. Its corporate headquarters are located in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 8, 2023 |
| -$6.20-10.71% vs estimate |
| $0.00 |
| Q3 2022 | Nov 14, 2022 | -$6.000.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.86-$0.25 (-12.08%)
Propanc Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
$0.00+$0.00 (0.0%)
Advanced Proteome Therapeutics Corporation: Healthcare · Biotechnology.
$0.00+$0.00 (+400.0%)
QuantRx Biomedical Corporation’s quoted price sits in the lower half of its reported 52-week range, 87.5% below the high.
$0.02-$0.00 (-5.0%)
Mycotopia Therapies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.44% below the high.
$0.00+$0.00 (+29,900.0%)
Miravant Medical Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.05 (-99.6%)
StatSure Diagnostic Systems, Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Cell Kinetics Ltd.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
PotNetwork Holdings, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
